Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAGUE-26: Catheter-directed Thrombolysis in Acute Pulmonary Embolism
NCT05493163Phase 4Completed
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Oct 2022
- Primary completion
- Mar 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms), sponsored by Faculty Hospital Kralovske Vinohrady. Primary endpoint: Composite of all-cause mortality, PE recurrence or cardiorespiratory decompensation at 7 days. Started Oct 2022; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT05493163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493163.